| Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma G Hudes, M Carducci, P Tomczak, J Dutcher, R Figlin, A Kapoor, ... New England Journal of Medicine 356 (22), 2271-2281, 2007 | 4610 | 2007 |
| Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial H Oettle, S Post, P Neuhaus, K Gellert, J Langrehr, K Ridwelski, ... Jama 297 (3), 267-277, 2007 | 2974 | 2007 |
| Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial P Sonneveld, IGH Schmidt-Wolf, B van der Holt, L El Jarari, U Bertsch, ... Journal of clinical oncology 30 (24), 2946-2955, 2012 | 1012 | 2012 |
| Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. IG Schmidt-Wolf, RS Negrin, HP Kiem, KG Blume, IL Weissman The Journal of experimental medicine 174 (1), 139-149, 1991 | 964 | 1991 |
| Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. IG Schmidt-Wolf, P Lefterova, BA Mehta, LP Fernandez, D Huhn, ... Experimental hematology 21 (13), 1673-1679, 1993 | 512 | 1993 |
| Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy H Pels, IGH Schmidt-Wolf, A Glasmacher, H Schulz, A Engert, V Diehl, ... Journal of Clinical Oncology 21 (24), 4489-4495, 2003 | 473 | 2003 |
| Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p K Neben, HM Lokhorst, A Jauch, U Bertsch, T Hielscher, B van der Holt, ... Blood, The Journal of the American Society of Hematology 119 (4), 940-948, 2012 | 461 | 2012 |
| Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial A Märten, D Flieger, S Renoth, S Weineck, P Albers, M Compes, ... Cancer Immunology, Immunotherapy 51, 637-644, 2002 | 419 | 2002 |
| RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group VI Gaidzik, L Bullinger, RF Schlenk, AS Zimmermann, J Röck, P Paschka, ... Journal of Clinical Oncology 29 (10), 1364-1372, 2011 | 397 | 2011 |
| Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial B Wittig, A Märten, T Dorbic, S Weineck, H Min, S Niemitz, B Trojaneck, ... Human gene therapy 12 (3), 267-278, 2001 | 376 | 2001 |
| Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC) C Hontscha, Y Borck, H Zhou, D Messmer, IGH Schmidt-Wolf Journal of cancer research and clinical oncology 137, 305-310, 2011 | 362 | 2011 |
| Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a … A Advani, B Coiffier, MS Czuczman, M Dreyling, J Foran, E Gine, ... Journal of Clinical Oncology 28 (12), 2085-2093, 2010 | 346 | 2010 |
| Non-viral and hybrid vectors in human gene therapy: an update GD Schmidt-Wolf, IGH Schmidt-Wolf Trends in molecular medicine 9 (2), 67-72, 2003 | 343 | 2003 |
| A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma A Glasmacher, C Hahn, F Hoffmann, R Naumann, H Goldschmidt, ... British journal of haematology 132 (5), 584-593, 2006 | 340 | 2006 |
| Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients A Glasmacher, A Prentice, M Gorschlüter, S Engelhart, C Hahn, ... Journal of Clinical Oncology 21 (24), 4615-4626, 2003 | 337 | 2003 |
| Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and … IGH Schmidt-Wolf, S Finke, B Trojaneck, A Denkena, P Lefterova, ... British journal of cancer 81 (6), 1009-1016, 1999 | 333 | 1999 |
| Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations A Märten, C Ziske, B Schöttker, S Renoth, S Weineck, P Buttgereit, ... Journal of immunotherapy 24 (6), 502-510, 2001 | 322 | 2001 |
| Neutropenic enterocolitis in adults: systematic analysis of evidence quality M Gorschlüter, U Mey, J Strehl, C Ziske, M Schepke, IGH Schmidt‐Wolf, ... European journal of haematology 75 (1), 1-13, 2005 | 314 | 2005 |
| Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial D Hoelzer, J Walewski, H Döhner, A Viardot, W Hiddemann, ... Blood, The Journal of the American Society of Hematology 124 (26), 3870-3879, 2014 | 303 | 2014 |
| High EVI1 Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities S Groeschel, S Lugthart, RF Schlenk, PJM Valk, K Eiwen, C Goudswaard, ... Journal of Clinical Oncology 28 (12), 2101-2107, 2010 | 284 | 2010 |
